RxDoctor Payments Data

Abbey Miller, PA

Physician Assistant · Amherst, NYNPI 1164819363

Payments from drug & device makers

$15,993in general payments, 2019–2025

Across 765 payments — averaging $20.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Livanova USA, Inc.$3K
  • UCB, Inc.$1K
  • Amgen$937
  • Teva Pharmaceuticals USA, Inc.$850
  • Lilly USA, LLC$715
  • plus $6K from 41 others

What the payments were for

  • Consulting fees$5854%
  • Travel & lodging$1,2798%
  • Food & beverage$14,13088%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,993 in reported general payments places this provider in the 95th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$33,660
Medicare patients
22
Services billed
3,640

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate25$29,924
QuliptaAtogepant20$21,779
Emgality PenGalcanezumab-Gnlm21$14,640
UbrelvyUbrogepant11$12,181
Aimovig AutoinjectorErenumab-Aooe13$9,681
Oxtellar XrOxcarbazepine12$7,288
Lamotrigine ErLamotrigine24$3,521
Topiramate ErTopiramate11$2,354
Topiramate33$605
Ondansetron OdtOndansetron31$600
Oxcarbazepine17$434
Baclofen21$270
Gabapentin23$270
Levetiracetam ErLevetiracetam13$224
Propranolol Hcl24$202

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieQulipta, Ubrelvy$3,433$33,96031 claims
PfizerNurtec Odt$549$29,92425 claims
Supernus Pharmaceuticals, Inc.Oxtellar Xr$41$7,28812 claims
Upsher-smith Laboratories LLCTopiramate$144$60533 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Amherst

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →